Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence
Metabolite profiling is being increasing employed in the study of prostate cancer as a means of identifying predictive, diagnostic, and prognostic biomarkers. This review provides a summary and critique of the current literature. Thirty-three human case-control studies of prostate cancer exploring d...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
American Association for Cancer Research (AACR)
2018
|
| Online Access: | http://hdl.handle.net/1721.1/116917 https://orcid.org/0000-0002-6702-4192 |
| _version_ | 1811086461553868800 |
|---|---|
| author | Kelly, R. S. Giovannucci, E. Mucci, L. A. Vander Heiden, Matthew G. |
| author2 | Koch Institute for Integrative Cancer Research at MIT |
| author_facet | Koch Institute for Integrative Cancer Research at MIT Kelly, R. S. Giovannucci, E. Mucci, L. A. Vander Heiden, Matthew G. |
| author_sort | Kelly, R. S. |
| collection | MIT |
| description | Metabolite profiling is being increasing employed in the study of prostate cancer as a means of identifying predictive, diagnostic, and prognostic biomarkers. This review provides a summary and critique of the current literature. Thirty-three human case-control studies of prostate cancer exploring disease prediction, diagnosis, progression, or treatment response were identified. All but one demonstrated the ability of metabolite profiling to distinguish cancer from benign, tumor aggressiveness, cases who recurred, and those who responded well to therapy. In the subset of studies where biomarker discriminatory ability was quantified, high AUCs were reported that would potentially outperform the current gold standards in diagnosis, prognosis, and disease recurrence, including PSA testing. There were substantial similarities between the metabolites and the associated pathways reported as significant by independent studies, and important roles for abnormal cell growth, intensive cell proliferation, and dysregulation of lipid metabolism were highlighted. The weight of the evidence therefore suggests metabolic alterations specific to prostate carcinogenesis and progression that may represent potential metabolic biomarkers. However, replication and validation of the most promising biomarkers is currently lacking and a number of outstanding methodologic issues remain to be addressed to maximize the utility of metabolomics in the study of prostate cancer. |
| first_indexed | 2024-09-23T13:26:17Z |
| format | Article |
| id | mit-1721.1/116917 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T13:26:17Z |
| publishDate | 2018 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | dspace |
| spelling | mit-1721.1/1169172022-10-01T15:18:12Z Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence Kelly, R. S. Giovannucci, E. Mucci, L. A. Vander Heiden, Matthew G. Koch Institute for Integrative Cancer Research at MIT Vander Heiden, Matthew G. Metabolite profiling is being increasing employed in the study of prostate cancer as a means of identifying predictive, diagnostic, and prognostic biomarkers. This review provides a summary and critique of the current literature. Thirty-three human case-control studies of prostate cancer exploring disease prediction, diagnosis, progression, or treatment response were identified. All but one demonstrated the ability of metabolite profiling to distinguish cancer from benign, tumor aggressiveness, cases who recurred, and those who responded well to therapy. In the subset of studies where biomarker discriminatory ability was quantified, high AUCs were reported that would potentially outperform the current gold standards in diagnosis, prognosis, and disease recurrence, including PSA testing. There were substantial similarities between the metabolites and the associated pathways reported as significant by independent studies, and important roles for abnormal cell growth, intensive cell proliferation, and dysregulation of lipid metabolism were highlighted. The weight of the evidence therefore suggests metabolic alterations specific to prostate carcinogenesis and progression that may represent potential metabolic biomarkers. However, replication and validation of the most promising biomarkers is currently lacking and a number of outstanding methodologic issues remain to be addressed to maximize the utility of metabolomics in the study of prostate cancer. National Institutes of Health (U.S.) (Grant P01 CA055075) National Institutes of Health (U.S.) (Grant CA133891) National Institutes of Health (U.S.) (Grant CA141298) National Institutes of Health (U.S.) (Grant CA136578) National Institutes of Health (U.S.) (Grant UM1 CA167552) 2018-07-11T20:07:11Z 2018-07-11T20:07:11Z 2016-04 2016-03 2018-07-11T17:42:20Z Article http://purl.org/eprint/type/JournalArticle 1055-9965 1538-7755 http://hdl.handle.net/1721.1/116917 Kelly, R. S. et al “Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.” Cancer Epidemiology Biomarkers & Prevention 25, 6 (April 2016): 887–906 © 2016 American Association for Cancer Research https://orcid.org/0000-0002-6702-4192 http://dx.doi.org/10.1158/1055-9965.EPI-15-1223 Cancer Epidemiology Biomarkers & Prevention Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf American Association for Cancer Research (AACR) PMC |
| spellingShingle | Kelly, R. S. Giovannucci, E. Mucci, L. A. Vander Heiden, Matthew G. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence |
| title | Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence |
| title_full | Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence |
| title_fullStr | Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence |
| title_full_unstemmed | Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence |
| title_short | Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence |
| title_sort | metabolomic biomarkers of prostate cancer prediction diagnosis progression prognosis and recurrence |
| url | http://hdl.handle.net/1721.1/116917 https://orcid.org/0000-0002-6702-4192 |
| work_keys_str_mv | AT kellyrs metabolomicbiomarkersofprostatecancerpredictiondiagnosisprogressionprognosisandrecurrence AT giovannuccie metabolomicbiomarkersofprostatecancerpredictiondiagnosisprogressionprognosisandrecurrence AT muccila metabolomicbiomarkersofprostatecancerpredictiondiagnosisprogressionprognosisandrecurrence AT vanderheidenmatthewg metabolomicbiomarkersofprostatecancerpredictiondiagnosisprogressionprognosisandrecurrence |